Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (381-390 of 539) with videos related to

Pageof 54
Sort By:
Leukemia & Lymphoma|March 18, 2017
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupHeinz Ludwig, Meletios A Dimopoulos, Philippe Moreau, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
The Oncologist|January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
Investigative Radiology|May 31, 2022
Combining Deep Learning and Radiomics for Automated, Objective, Comprehensive Bone Marrow Characterization From Whole-Body MRI: A Multicentric Feasibility StudyMarkus Wennmann, André Klein, Fabian Bauer, et al.
Pageof 54

Showing results (381-390 of 539) with videos related to

Sort By:
Pageof 54
Leukemia & Lymphoma|March 18, 2017
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupHeinz Ludwig, Meletios A Dimopoulos, Philippe Moreau, et al.
Expert Opinion on Investigational Drugs|July 14, 2025
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directionsPaul G Richardson, Elisabeth K O'Donnell, Peter O'Gorman, et al.
Blood|February 27, 2026
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ studyRobert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
The Oncologist|January 21, 2010
Current multiple myeloma treatment strategies with novel agents: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
Investigative Radiology|May 31, 2022
Combining Deep Learning and Radiomics for Automated, Objective, Comprehensive Bone Marrow Characterization From Whole-Body MRI: A Multicentric Feasibility StudyMarkus Wennmann, André Klein, Fabian Bauer, et al.
Pageof 54